Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
Novartis backs away from NASH, furthering its research revamp
BioPharma Dive
Sun, 02/26/23 - 10:16 pm
Novartis
NASH
Pliant Therapeutics
PLN-1474
Janssen Returns Phase I NASH Candidate to Arrowhead
BioSpace
Wed, 02/15/23 - 06:08 pm
JNJ
Janssen
RNAi
Arrowhead Pharmaceuticals
NASH
Nimbus hopes to strike thrice
EP Vantage
Tue, 02/7/23 - 11:08 am
Nimbus Therapeutics
NASH
firsocostat
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
Clinical Trials Arena
Thu, 01/26/23 - 10:51 am
FDA
Intercept Pharma
OCA
obeticholic acid
NASH
By summer solstice, we'll know the fate of Intercept's NASH drug
Endpoints
Thu, 01/19/23 - 09:39 am
Intercept Pharmaceuticals
FDA
NASH
obeticholic acid
OCA
Madrigal shares triple on positive NASH study results
BioPharma Dive
Mon, 12/19/22 - 12:22 pm
Madrigal Pharmaceuticals
clinical trials
NASH
resmetirom
Axcella axes NASH program, 85% of staff in last-ditch focus on long COVID
Fierce Biotech
Thu, 12/15/22 - 11:18 am
Axcella Therapeutics
NASH
layoffs
COVID-19
Long COVID
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
BioSpace
Mon, 12/12/22 - 10:13 am
NASH
Intercept Pharma
Novo Nordisk
Madrigal Pharmaceuticals
Inventiva
Galmed Pharmaceuticals
Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out
Fierce Biotech
Tue, 11/1/22 - 12:09 pm
Pfizer
R&D
NASH
breast cancer
eczema
Ocaliva fails NASH trial just as Intercept charts path toward FDA application
Fierce Pharma
Fri, 09/30/22 - 12:31 pm
Intercept Pharma
NASH
obeticholic acid
Ocaliva
clinical trials
FDA
With cash dwindling, Axcella shares look at blinded NASH data
Fierce Biotech
Thu, 09/29/22 - 10:11 am
Axcella
NASH
clinical trials
AXA1125
Biotech’s near-term key catalysts
EP Vantage
Thu, 09/29/22 - 09:45 am
Biogen
Eisai
Alzheimer's disease
Arrowhead Pharmaceuticals
Takeda
RNAi
Madrigal
NASH
Ascendis
FDA
Altimmune sees phase 1 success in tricky NASH indication with GLP-1 agonist
Fierce Biotech
Wed, 09/14/22 - 08:06 pm
Altimmune
NASH
clinical trials
pemvidutide
Oramed phase 2 insulin drug data ‘paint an exciting picture’ in rocky NASH landscape
Fierce Biotech
Tue, 09/13/22 - 07:56 pm
Oramed
NASH
diabetes
Pfizer
insulin
clinical trials
ORMD-0801
Akero hits endpoints in midphase NASH trial, linking candidate to improvements in fibrosis
Fierce Biotech
Tue, 09/13/22 - 10:40 am
Akero Therapeuticsw
NASH
liver fibrosis
clinical trials
efruxifermin
Hepion screens first subject in Phase IIb trial of NASH drug
Clinical Trials Arena
Thu, 09/1/22 - 10:42 am
Hepion Pharmaceuticals
NASH
clinical trials
rencofilstat
A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity
Fierce Pharma
Mon, 08/29/22 - 10:40 am
Novo Nordisk
semaglutide
NASH
Alzheimer's disease
Saxenda
obesity
The NASH curse strikes again. Pfizer dumps early-stage asset for liver condition
Fierce Biotech
Thu, 07/28/22 - 11:08 am
Pfizer
PF-06882961
NASH
Novartis looking for new homes for midphase asthma, eye disease and NASH assets after pipeline review
Fierce Biotech
Tue, 07/19/22 - 10:36 am
Novartis
asthma
NASH
Retinitis pigmentosa
Beyond biopsy: how noninvasive NASH tests can move the needle
Clinical Trials Arena
Fri, 07/15/22 - 12:09 pm
liver biopsies
diagnostics
NASH
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »